シミズ　キヨウコ   SHIMIZU Kyoko   清水　京子    所属   その他 その他    職種   非常勤嘱託
論文種別	原著
言語種別	英語
査読の有無	査読なし
表題	A Multicenter Phase II Study of Gemcitabine plus S-1 Chemotherapy for Advanced Biliary Tract Cancer.
掲載誌名	正式名：Anticancer research 略　 称：Anticancer Res ISSNコード：17917530/02507005
巻・号・頁	37(2),pp.909-914
著者・共著者	Arima Shiho, Shimizu Kyoko, Okamoto Tomoyoshi, Toki Masao, Suzuki Yutaka, Okano Naohiro, Naruge Daisuke, Kawai Kirio, Kobayashi Takaaki, Kasuga Akiyoshi, Kitamura Hiroshi, Takasu Atuko, Nagashima Fumio, Sugiyama Masanori, Furuse Junji
担当区分	2nd著者
発行年月	2017/02
概要	BACKGROUND:Gemcitabine (GEM) plus cisplatin (CDDP) chemotherapy has been used worldwide as the standard first-line treatment for advanced biliary tract cancer (BTC). A phase II trial has also suggested promising activity of GEM plus S-1 chemotherapy against advanced BTC. The aim of this study was to evaluate the efficacy and safety of GEM plus S-1 chemotherapy in patients with advanced BTC.PATIENTS AND METHODS:The eligibility criteria were as follows: histologically-proven BTC, unresectable or recurrent disease, ECOG performance status (PS) 0-1 regardless of previous treatment. Gemcitabine was administered intravenously at the dose of 1,000 mg/m2 over 30 min on days 1 and 8, and S-1 was administered orally at doses of 60/80/100 mg/day based on the BSA, from day 1 to day 14, every 3 weeks. The primary endpoint was the response rate according to RECIST, ver. 1.1, and the secondary endpoints were the frequency/severity of toxicities, progression-free survival (PFS) and overall survival (OS).RESULTS:A total of 38 patients were enrolled between August 2008 and November 2011. There were 19 men and 19 women, with a median age of 66 years (range=44-81 years). Seven patients had a previous history of first-line or adjuvant chemotherapy after surgery. The PS was 0 and 1 in 30 and 7 patients, respectively. The treatment response was classified as partial response in 6 patients (15.8%) and as stable disease in 18 patients (47.4%). The median PFS and OS were 5.8 and 15.9 months, respectively. The toxicity was generally mild, and the most common grade 3/4 toxicities were leukopenia (31.6%), neutropenia (36.8%), nausea/vomiting (2.6%), and diarrhea (2.6%). There was one treatment-related death due to interstitial pneumonia.CONCLUSION:Our study revealed that gemcitabine plus S-1 chemotherapy was well-tolerated and exhibited favorable antitumor activity in patients with advanced BTC.
DOI	10.21873/anticanres.11398
PMID	28179351